This pathophysiology extends far beyond the well-characterized amyloid and tau pathology and has been shown to include not only metabolic dysfunction and neuroinflammation but also widespread synaptic loss which is often accompanied by neuronal loss as AD progresses (Tönnies and Trushina, 2017). The gene discussed is MAPT; the disease is Alzheimer disease.